{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:05:15Z","timestamp":1790856315850,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972628"],"award-info":[{"award-number":["81972628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32100756"],"award-info":[{"award-number":["32100756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Fund for Medical Sciences of Chinese Academy of Medical Sciences","award":["2021- I2M-1-021"],"award-info":[{"award-number":["2021- I2M-1-021"]}]},{"name":"Innovation Fund for Medical Sciences of Chinese Academy of Medical Sciences","award":["2021- I2M-1-066"],"award-info":[{"award-number":["2021- I2M-1-066"]}]},{"name":"Collaboration Fund of CHCAMS and CHCAMS-Shenzhen Hospital","award":["CFA202201009"],"award-info":[{"award-number":["CFA202201009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Variated anti-cancer therapies are combined with immune checkpoint blockades (ICBs) for improving ICB therapeutic efficacy. Occurrence of tissue damage is common that triggers multiple inflammatory cytokine generation. Gastrointestinal organs are the commonly affected. We investigated the impact of acute colitis on tumor infiltration of antigen-specific CD8\n                      <jats:sup>+<\/jats:sup>\n                      cytotoxic T lymphocytes (CTLs) for controlling tumor growth and responding to antibody against PD-1 (anti-PD-1).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Several tumor cell lines were inoculated into syngeneic mice subcutaneously or intra-hepatically. When tumor mass formed, activated CTLs were intravenously transferred into the tumor-bearing mice, that were given the drinking water containing 2% dextran sulfate sodium (DSS) for acute colitis induction. Tumor growth, infiltration of two exhausted CTL subsets, and the CTL interaction with tumor vascular endothelium were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Acute colitis dampened CTL-mediated antitumor effects, correlating with IL-17A elevation in the inflamed intestine. In the tumor bed, stem-like exhausted CTLs, which were defined as PD-1\n                      <jats:sup>+<\/jats:sup>\n                      Slamf6\n                      <jats:sup>+<\/jats:sup>\n                      Tim3\n                      <jats:sup>\u2212<\/jats:sup>\n                      , expressed higher IL-17A receptor heterodimers and lower leukocyte function-associated antigen-1 (LFA-1) than terminally exhausted CTLs did, that were defined as PD-1\n                      <jats:sup>+<\/jats:sup>\n                      Slamf6\n                      <jats:sup>\u2212<\/jats:sup>\n                      Tim3\n                      <jats:sup>+<\/jats:sup>\n                      . IL-17A stimulation reduced LFA-1 surface expression on stem-like exhausted CTLs and the counterpart ICAM-1 (intracellular adhesion molecule-1) on tumor vascular endothelium. IL-17A stimulation suppressed the extravasation across tumor vascular endothelium and self-renewal of stem-like, not the terminally exhausted CTLs. Administration of anti-IL-17A neutralizing antibody to the colitis mice restored the CTL tumor infiltration and enhanced anti-PD-1 treatment efficacy against tumors. In 33 hepatocellular carcinoma patients being treated with anti-PD-1 plus antibody against vascular endothelial growth factor, disease progression of 15 patients, that exhibited serum IL-17A increase 24\u00a0h post-therapy as compared to pre-therapy level, was poorer than that of 18 patients that exhibited serum IL-17A no-increase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Abnormal generation of IL-17A mainly repressed tumor infiltration of stem-like exhausted CTLs. ICB-based immunotherapeutic efficacy could be upgraded with administration of anti-IL-17A, when treatment-related IL-17A elevation occurred due to tissue damage, such as acute colitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-023-03026-y","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:02:54Z","timestamp":1692615774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8+ T cells to demote the antitumor immunity"],"prefix":"10.1186","volume":"21","author":[{"given":"Ruochan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"issue":"21","key":"3026_CR1","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337.","journal-title":"Cell"},{"key":"3026_CR2","doi-asserted-by":"crossref","first-page":"102440","DOI":"10.1016\/j.ctrv.2022.102440","volume":"109","author":"DL Nielsen","year":"2022","unstructured":"Nielsen DL, Juhl CB, Chen IM, Kellermann L, Nielsen OH. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treat Rev. 2022;109:102440.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3026_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3026_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2008.10.018","volume":"136","author":"M Leppkes","year":"2009","unstructured":"Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, Pouly S, Murphy AJ, Valenzuela DM, Yancopoulos GD, et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009;136(1):257\u201367.","journal-title":"Gastroenterology"},{"key":"3026_CR5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev-immunol-101819-092536","volume":"39","author":"S Majumder","year":"2021","unstructured":"Majumder S, McGeachy MJ. IL-17 in the pathogenesis of disease: good intentions gone Awry. Annu Rev Immunol. 2021;39:537\u201356.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"3026_CR6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","volume":"20","author":"X Li","year":"2019","unstructured":"Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor-based signaling and implications for disease. Nat Immunol. 2019;20(12):1594\u2013602.","journal-title":"Nat Immunol"},{"issue":"7","key":"3026_CR7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-13-2534","volume":"74","author":"S Ma","year":"2014","unstructured":"Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, Shi L, Wu D, Dong C, Liu H. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Can Res. 2014;74(7):1969\u201382.","journal-title":"Can Res"},{"issue":"7556","key":"3026_CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels L, Jonkers J, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345\u20138.","journal-title":"Nature"},{"issue":"6","key":"3026_CR9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1158\/1078-0432.CCR-16-0617","volume":"23","author":"TJ Li","year":"2017","unstructured":"Li TJ, Jiang YM, Hu YF, Huang L, Yu J, Zhao LY, Deng HJ, Mou TY, Liu H, Yang Y, et al. Interleukin-17-Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer. Clin Cancer Res. 2017;23(6):1575\u201385.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3026_CR10","doi-asserted-by":"crossref","first-page":"e20190354","DOI":"10.1084\/jem.20190354","volume":"217","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, Zoltan M, Arora N, Baydogan S, Horne W, et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med. 2020;217(12);217(12):e20190354.","journal-title":"J Exp Med"},{"key":"3026_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2018.10.022","volume":"118","author":"D Ribatti","year":"2019","unstructured":"Ribatti D. Interleukins as modulators of angiogenesis and anti-angiogenesis in tumors. Cytokine. 2019;118:3\u20137.","journal-title":"Cytokine"},{"issue":"1","key":"3026_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20171849","volume":"216","author":"X Chen","year":"2019","unstructured":"Chen X, Cai G, Liu C, Zhao J, Gu C, Wu L, Hamilton TA, Zhang CJ, Ko J, Zhu L, et al. IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1(+) stem cells. J Exp Med. 2019;216(1):195\u2013214.","journal-title":"J Exp Med"},{"issue":"1","key":"3026_CR13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s40425-019-0757-z","volume":"7","author":"J Chen","year":"2019","unstructured":"Chen J, Ye X, Pitmon E, Lu M, Wan J, Jellison ER, Adler AJ, Vella AT, Wang K. IL-17 inhibits CXCL9\/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors. J Immunother Cancer. 2019;7(1):324.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3026_CR14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nm.3291","volume":"19","author":"AS Chung","year":"2013","unstructured":"Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114\u201323.","journal-title":"Nat Med"},{"issue":"5","key":"3026_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509\u201323. e506.","journal-title":"Cancer Cell"},{"issue":"12","key":"3026_CR16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/cmi.2017.124","volume":"14","author":"W Zhong","year":"2017","unstructured":"Zhong W, Li Q. Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation. Cell Mol Immunol. 2017;14(12):1020\u20132.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3026_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nm.2999","volume":"19","author":"M Bruchard","year":"2013","unstructured":"Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57\u201364.","journal-title":"Nat Med"},{"key":"3026_CR18","doi-asserted-by":"crossref","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B, Zhong R, Xiong S, Li J, Chen Z, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021;41:101134.","journal-title":"EClinicalMedicine"},{"issue":"7620","key":"3026_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417\u201321.","journal-title":"Nature"},{"issue":"2","key":"3026_CR20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","volume":"45","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, Danilo M, Alfei F, Hofmann M, Wieland D, et al. T Cell Factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415\u201327.","journal-title":"Immunity"},{"issue":"1","key":"3026_CR21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019;50(1):195\u2013211. e110.","journal-title":"Immunity"},{"issue":"3","key":"3026_CR22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"issue":"5","key":"3026_CR23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3026_CR24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nri3908","volume":"15","author":"D Vestweber","year":"2015","unstructured":"Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015;15(11):692\u2013704.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"3026_CR25","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"1","key":"3026_CR26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/2326-6066.CIR-19-0210","volume":"8","author":"K Chen","year":"2020","unstructured":"Chen K, Wu Z, Zhao H, Wang Y, Ge Y, Wang D, Li Z, An C, Liu Y, Wang F, et al. XCL1\/Glypican-3 fusion gene immunization generates potent antitumor cellular immunity and enhances anti-PD-1 efficacy. Cancer Immunol Res. 2020;8(1):81\u201393.","journal-title":"Cancer Immunol Res"},{"key":"3026_CR27","doi-asserted-by":"crossref","first-page":"718617","DOI":"10.1155\/2012\/718617","volume":"2012","author":"M Perse","year":"2012","unstructured":"Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:718617.","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"3026_CR28","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1172\/JCI129025","volume":"129","author":"DK Nambiar","year":"2019","unstructured":"Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, et al. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Investig. 2019;129(12):5553\u201367.","journal-title":"J Clin Investig"},{"issue":"12","key":"3026_CR29","doi-asserted-by":"crossref","first-page":"e85032","DOI":"10.1371\/journal.pone.0085032","volume":"8","author":"X Xing","year":"2013","unstructured":"Xing X, Yang J, Yang X, Wei Y, Zhu L, Gao D, Li M. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013;8(12):e85032.","journal-title":"PLoS One"},{"issue":"2","key":"3026_CR30","doi-asserted-by":"crossref","first-page":"e0247238","DOI":"10.1371\/journal.pone.0247238","volume":"16","author":"Z Sun","year":"2021","unstructured":"Sun Z, Nyberg R, Wu Y, Bernard B, Redmond WL. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. PLoS One. 2021;16(2):e0247238.","journal-title":"PLoS One"},{"issue":"385","key":"3026_CR31","doi-asserted-by":"crossref","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH. Laoui D et al: Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670.","journal-title":"Sci Transl Med"},{"issue":"16","key":"3026_CR32","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-21-3972","volume":"28","author":"W Zhang","year":"2022","unstructured":"Zhang W, Gong C, Peng X, Bi X, Sun Y, Zhou J, Wu F, Zeng H, Wang Y, Zhou H, et al. Serum concentration of CD137 and tumor infiltration by M1 macrophages predict the response to sintilimab plus bevacizumab biosimilar in advanced hepatocellular carcinoma patients. Clin Cancer Res. 2022;28(16):3499\u2013508.","journal-title":"Clin Cancer Res"},{"issue":"36","key":"3026_CR33","doi-asserted-by":"crossref","first-page":"eaau9657","DOI":"10.1126\/sciimmunol.aau9657","volume":"4","author":"Y Su","year":"2019","unstructured":"Su Y, Huang J, Zhao X, Lu H, Wang W, Yang XO, Shi Y, Wang X, Lai Y, Dong C. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4(36):eaau9657.","journal-title":"Sci Immunol"},{"issue":"5","key":"3026_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/BF02723062","volume":"32","author":"SJ Wang","year":"1996","unstructured":"Wang SJ, Greer P, Auerbach R. Isolation and propagation of yolk-sac-derived endothelial cells from a hypervascular transgenic mouse expressing a gain-of-function fps\/fes proto-oncogene. In Vitro Cell Dev Biol Anim. 1996;32(5):292\u20139.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"16","key":"3026_CR35","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.cell.2022.06.010","volume":"185","author":"JO Lundberg","year":"2022","unstructured":"Lundberg JO, Weitzberg E. Nitric oxide signaling in health and disease. Cell. 2022;185(16):2853\u201378.","journal-title":"Cell"},{"issue":"12","key":"3026_CR36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41565-019-0570-3","volume":"14","author":"YC Sung","year":"2019","unstructured":"Sung YC, Jin PR, Chu LA, Hsu FF, Wang MR, Chang CC, Chiou SJ, Qiu JT, Gao DY, Lin CC, et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol. 2019;14(12):1160\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"3026_CR37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41467-022-29121-x","volume":"13","author":"J Kim","year":"2022","unstructured":"Kim J, Francis DM, Sestito LF, Archer PA, Manspeaker MP, O\u2019Melia MJ, Thomas SN. Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy. Nat Commun. 2022;13(1):1479.","journal-title":"Nat Commun"},{"issue":"6","key":"3026_CR38","doi-asserted-by":"crossref","first-page":"e002603","DOI":"10.1136\/jitc-2021-002603","volume":"9","author":"BS Kim","year":"2021","unstructured":"Kim BS, Kuen DS, Koh CH, Kim HD, Chang SH, Kim S, Jeon YK, Park YJ, Choi G, Kim J, et al. Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer. J Immunother Cancer. 2021;9(6):e002603.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3026_CR39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L, Bellard E, Veerman K, Bettini S, Lafouresse F, Vina E, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022;40(3):318\u201334. e319.","journal-title":"Cancer Cell"},{"issue":"13","key":"3026_CR40","doi-asserted-by":"crossref","first-page":"e154152","DOI":"10.1172\/JCI154152","volume":"132","author":"A Hickman","year":"2022","unstructured":"Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, Punt S, Williams L, et al. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022;132(13):e154152.","journal-title":"J Clin Invest"},{"issue":"3","key":"3026_CR41","first-page":"1","volume":"7","author":"ZY Feng","year":"2021","unstructured":"Feng ZY, Xu FG, Liu M, Xu HJ, Wu FB, Chen HB, Xia HP. The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma. Hepatoma Res. 2021;7(3):1\u201315.","journal-title":"Hepatoma Res"},{"issue":"6","key":"3026_CR42","doi-asserted-by":"crossref","first-page":"e20210693","DOI":"10.1084\/jem.20210693","volume":"219","author":"X Chen","year":"2022","unstructured":"Chen X, Zhao J, Herjan T, Hong L, Liao Y, Liu C, Vasu K, Wang H, Thompson A, Fox PL, et al. IL-17-induced HIF1alpha drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion. J Exp Med. 2022;219(6):e20210693.","journal-title":"J Exp Med"},{"issue":"4","key":"3026_CR43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP, Chiplunkar SV. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer. 2016;139(4):869\u201381.","journal-title":"Int J Cancer"},{"issue":"4","key":"3026_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/cvr\/cvs422","volume":"97","author":"H Nguyen","year":"2013","unstructured":"Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013;97(4):696\u2013704.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"3026_CR45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11906-021-01128-7","volume":"23","author":"GK Davis","year":"2021","unstructured":"Davis GK, Fehrenbach DJ, Madhur MS. Interleukin 17A: key player in the pathogenesis of hypertension and a potential therapeutic target. Curr Hypertens Rep. 2021;23(3):13.","journal-title":"Curr Hypertens Rep"},{"issue":"410","key":"3026_CR46","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9(410):eaan5616.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3026_CR47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"49","key":"3026_CR48","doi-asserted-by":"crossref","first-page":"eaaw2262","DOI":"10.1126\/sciimmunol.aaw2262","volume":"5","author":"SN Harbour","year":"2020","unstructured":"Harbour SN, DiToro DF, Witte SJ, Zindl CL, Gao M, Schoeb TR, Jones GW, Jones SA, Hatton RD, Weaver CT. T(H)17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Science immunology. 2020;5(49):eaaw2262.","journal-title":"Science immunology"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-03026-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-03026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:23:22Z","timestamp":1700605402000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-03026-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3026"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-03026-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"29 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences (Approval No. 18\u2013126\/1704). Study protocols involving mice were approved by the Institutional Animal Care and Use Committee at NCC\/CH, CAMS (NCC2021A037).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}